JP2024536201A - 抗ガレクチン－９抗体及びその治療的使用 - Google Patents

抗ガレクチン－９抗体及びその治療的使用 Download PDF

Info

Publication number
JP2024536201A
JP2024536201A JP2024519470A JP2024519470A JP2024536201A JP 2024536201 A JP2024536201 A JP 2024536201A JP 2024519470 A JP2024519470 A JP 2024519470A JP 2024519470 A JP2024519470 A JP 2024519470A JP 2024536201 A JP2024536201 A JP 2024536201A
Authority
JP
Japan
Prior art keywords
galectin
antibody
dose
subject
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024519470A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024536201A5 (https=
Inventor
フィリポヴィッチ，アレクサンドラ
エレンコ，エリック
ペイドン，ヘザー
コース，クリストファー
サハスラナマン，スリクマール
ブダ，ネージシュワー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Puretech LYT Inc
Original Assignee
Puretech LYT Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Puretech LYT Inc filed Critical Puretech LYT Inc
Publication of JP2024536201A publication Critical patent/JP2024536201A/ja
Publication of JP2024536201A5 publication Critical patent/JP2024536201A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
JP2024519470A 2021-10-01 2022-09-30 抗ガレクチン－９抗体及びその治療的使用 Pending JP2024536201A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163251227P 2021-10-01 2021-10-01
US63/251,227 2021-10-01
US202163277384P 2021-11-09 2021-11-09
US63/277,384 2021-11-09
PCT/US2022/077408 WO2023056461A1 (en) 2021-10-01 2022-09-30 Anti-galectin-9 antibodies and therapeutic uses thereof

Publications (2)

Publication Number Publication Date
JP2024536201A true JP2024536201A (ja) 2024-10-04
JP2024536201A5 JP2024536201A5 (https=) 2025-10-08

Family

ID=85783695

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024519470A Pending JP2024536201A (ja) 2021-10-01 2022-09-30 抗ガレクチン－９抗体及びその治療的使用

Country Status (9)

Country Link
US (1) US20250269019A1 (https=)
EP (1) EP4392068A4 (https=)
JP (1) JP2024536201A (https=)
KR (1) KR20240082393A (https=)
AU (1) AU2022355201A1 (https=)
CA (1) CA3233331A1 (https=)
IL (1) IL311796A (https=)
MX (1) MX2024004012A (https=)
WO (1) WO2023056461A1 (https=)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7581238B2 (ja) * 2019-05-01 2024-11-12 ニューヨーク・ユニバーシティ 抗ガレクチン９抗体およびその使用
US20220332832A1 (en) * 2019-08-01 2022-10-20 New York University Combined cancer therapy of anti-galectin-9 antibodies and chemotherapeutics

Also Published As

Publication number Publication date
CA3233331A1 (en) 2023-04-06
IL311796A (en) 2024-05-01
EP4392068A4 (en) 2026-03-11
AU2022355201A1 (en) 2024-04-04
WO2023056461A1 (en) 2023-04-06
EP4392068A1 (en) 2024-07-03
KR20240082393A (ko) 2024-06-10
US20250269019A1 (en) 2025-08-28
MX2024004012A (es) 2024-07-01

Similar Documents

Publication Publication Date Title
TW201806616A (zh) 抗－ｐｄ－１抗體與輻射治療癌症之組合
KR20200112867A (ko) 길항적 항-pd-1 항체로 암을 치료하는 방법
AU2020319899B2 (en) Combined cancer therapy of anti-galectin-9 antibodies and chemotherapeutics
CN114026126A (zh) 抗半乳糖凝集素-9抗体及其用途
JP2017519757A (ja) 慢性リンパ球性白血病（ｃｌｌ）の処置
US20240043543A1 (en) Anti-galectin-9 antibodies and therapeutic uses thereof
US20240109972A1 (en) Antibody and taxane combination therapy
US20240109968A1 (en) Anti-galectin-9 antibodies and therapeutic uses thereof
JP2023554422A (ja) がんの治療のための多重特異性抗体
US20240182583A1 (en) Combination of anti-galectin-9 antibodies and chemotherapeutics for use in cancer therapy
US20240190970A1 (en) Anti-galectin-9 antibodies and therapeutic uses thereof
JP2025522729A (ja) ガレクチン－９を阻害する抗体を用いた悪性血液疾患の処置
JP2024536201A (ja) 抗ガレクチン－９抗体及びその治療的使用
HK40112915A (zh) 抗半乳糖凝集素-9抗体及其治疗用途
CN118251234A (zh) 抗半乳糖凝集素-9抗体及其治疗用途
WO2025085792A1 (en) Treatment of hematological malignancies with antibodies inhibiting galectin-9
HK40121853A (zh) 用抑制半乳糖凝集素-9的抗体治疗血液恶性肿瘤
HK40108543A (zh) 在癌症疗法中使用的抗半乳糖凝集素-9抗体和化疗剂的组合
CN117500522A (zh) 抗半乳糖凝集素-9抗体及其治疗用途
CN117580589A (zh) 在癌症疗法中使用的抗半乳糖凝集素-9抗体和化疗剂的组合
HK40069657A (en) Anti-galectin-9 antibodies and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250930

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250930